Baron Opportunity Fund (BIOPX)

Portfolio Management

Michael Lippert

Fund Manager since 2006

View All Commentary by Michael

Fund Description

Baron Opportunity Fund invests in innovative high-growth companies.



Portfolio Commentary

Retail Performance

Review and Outlook (for quarter ended 6/30/2016)

Through much of the second quarter, the market continued to recover nicely from the sharp risk-off mindset that prevailed the first six weeks of the year. In January and February, investors appeared to put significant weight on macro downside risks: a sharp economic slowdown in China, the end of the U.S. economic recovery, persistent low and even negative sovereign interest rates, collapsing oil prices, etc. It appears that concerns over these fears have turned more optimistic as the data (including expanding U.S. leading indicators, rising oil prices, and declining high yield credit spreads) has improved. In the last week of the quarter, the surprising Brexit vote drove a temporary sell-off in the market.

While we, of course, stay well-versed on such things as the domestic and global economy, the Fed, terrorism and military actions, politics, and anomalous events like Brexit, these have little impact on Baron’s investing philosophy and approach. Yes, Brexit has created uncertainty regarding whether Great Britain will abide by the referendum vote and leave the European Union; what the terms of an exit, if it occurs, will ultimately be; and what impact an exit or merely the risk of one will have on the global economy and the tone of the world’s stock markets. While we intend to stay informed, it is almost impossible to predict what will happen. Who would have thought that all British politicians involved in both sides of the Brexit vote would have lost power? Or that the market would have shot up after just a two-day sell-off? We have not made any changes to the portfolio due to Brexit alone and have no present intention of doing so.

With Baron Opportunity Fund, we aim to offer our investors a portfolio focused on high growth, innovative businesses capitalizing on powerful secular trends – a Fund highly differentiated from a passive index or ETF, as well as a generalized growth fund. We aim to differentiate not by trying to figure out cyclical growth drivers but by focusing, almost exclusively, on secular growth. We seek to identify powerful long-term trends – which we refer to as generational, paradigm, or tectonic shifts – that will drive robust growth regardless of the strength or weakness of the underlying economy.

Some of the secular themes in which we invest include cloud computing and software-as-a-service (SaaS), mobile, big data, digital media, targeted digital advertising, e-commerce, genetics, electronic medical records, immune-oncology, cybersecurity, electric vehicles and autonomous driving, and electronic payments. These themes span industries and represent the world’s future, not its past. They are visible, impactful, and persistent. They will play out over a long period of time, literally 10 years or more. They will disrupt existing industry dynamics. We believe the winners will capture large profit pools from the legacy way of doing things. By investing in these themes, our goal is to deliver dependable high-growth rates that are greater than the general economy, as reflected in broad market indexes, although we cannot guarantee it.

Top Contributors/Detractors to Performance

Contributors (for quarter ended 6/30/2016)
  • Shares of, Inc., the world’s largest retailer and cloud services provider, rose in Q2 on strong revenue growth and improving margins in the core business. Amazon’s other major business segment, Amazon Web Services (AWS) continues to gain traction with enterprise customers, and had another strong quarter of growth. Over time, we expect AWS to be the larger contributor to value creation. Amazon continues to invest in new and potentially large business segments such as e-finance, business supplies, and apparel.

  • Shares of CoStar Group, Inc., a real estate information and marketing services company, increased on outstanding financial results. Revenue growth accelerated to 25%, margins expanded 14% year over year, and earnings almost tripled. CoStar grew in its core commercial real estate market and captured share in the multifamily space. We believe CoStar is poised to generate accelerating organic revenue growth and significant margin expansion as it leverages recent investments in sales headcount, product expansion, and multifamily marketing.

  • Shares of property and casualty insurance software vendor Guidewire Software, Inc. increased in Q2. Guidewire enjoys near-perfect retention rates, a growing installed base, and accelerating adoption. The company is early in its core system replacement cycle, and is expanding its addressable market through persistent innovation. We believe Accenture’s April sale of rival insurance software vendor Duck Creek and its new relationship with Guidewire will help to enhance pricing and win rates and shorten sales cycles.

Detractors (for quarter ended 6/30/2016)
  • Shares of DNA sequencing company Illumina, Inc. fell in Q2 on first quarter revenue that missed Street expectations and a lowered forecast for 2016 due to weak first quarter sales of its HiSeq instrument line and a lower forecast for Europe. Management believes the issues are short-term, fixable, and unrelated to fundamental market demand. We continue to believe Illumina has a long runway for growth driven by increasing adoption of DNA sequencing in clinical markets such as cancer screening, diagnosis, and treatment.

  • Alphabet Inc. is the world’s largest search and online advertising-related company. Shares of Alphabet were driven down by Q1 results that missed Street expectations. We believe that while desktop search is becoming a more mature business for the company, Alphabet is well positioned to benefit from substantial growth in mobile and online video advertising.

  • Pacira Pharmaceuticals, Inc., a pharmaceutical that makes pain control drug EXPAREL, had a watershed event in mid-December 2015 when it won a favorable settlement of a marketing dispute with the FDA. Pacira received broad, definitive labeling for many major surgical uses. Shares peaked earlier in 2016, but have since dropped due to broader concerns in the pharma sector as well as growth guidance biased toward the second half of 2016. We believe Pacira has the potential for 25-35% top line growth for years to come.

Quarterly Attribution Analysis (for quarter ended 6/30/2016)

The Quarterly Attribution Analysis for period ending June 30, 2016 is not yet available

Back to Top

Invest In Baron Funds Today

The prospective performance of the companies discussed herein is based on our internal analysis and reflect our opinions only. We cannot promise future returns and our opinions are a reflection of our best judgement at the time of publication. Our views are not intended as recommendations or investment advice to any person and are subject to change at any time based on market and other conditions and Baron has no obligation to update them. Investing in the stock market is always risky. Current and future portfolio holdings in the Fund are subject to risk.

Source: FactSet PA